Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts

Area of Science:

• Immunology
• Transplantation Science
• Hematopoietic Stem Cell Biology

Background:

• Solid organ and cellular graft transplantation are routine but necessitate lifelong immunosuppression.
• Current immunosuppression strategies carry risks of infection, malignancy, end-organ toxicity, and chronic rejection.
• Donor-specific transplantation tolerance remains a critical unmet goal in transplantation.

Purpose of the Study:

• To review concepts of hematopoietic chimerism as a strategy for inducing transplantation tolerance.
• To focus on macrochimerism, defined as the engraftment of hematopoietic stem cells via bone marrow transplantation (BMT).
• To discuss the advantages and limitations of BMT in achieving macrochimerism and tolerance.

Main Methods:

• Review of existing literature on hematopoietic chimerism and transplantation tolerance.
• Focus on mixed allogeneic chimerism (macrochimerism) induced by bone marrow transplantation (BMT).
• Analysis of the benefits and drawbacks associated with BMT procedures.

Main Results:

• Hematopoietic chimerism, specifically macrochimerism via BMT, is a promising avenue for transplantation tolerance.
• BMT facilitates the engraftment of donor hematopoietic stem cells, potentially leading to reduced or eliminated immunosuppression.
• Current BMT approaches have limitations that need to be addressed for broader clinical application.

Conclusions:

• Hematopoietic chimerism through BMT offers a potential solution to the challenges of lifelong immunosuppression in transplantation.
• Further research and development are needed to overcome the limitations of BMT and optimize its use for inducing tolerance.
• Achieving stable macrochimerism is key to realizing the goal of donor-specific transplantation tolerance.